The legalization of Cannabis in many states and countries has pushed insurance companies to rethink their strategy. Recently, insurance companies in Canada are no longer considering cannabis as a high-risk substance like Tobacco. The legalization has turned the companies to look at young people as long-term clients. The recent update in policies by some of the biggest insurance companies will have a major impact on user premiums.

Since 2016, insurance companies are slowly moving cannabis from a high-risk category to a category where premiums are not affected. By removing medical cannabis from high-risk factors, the insurance application will rely on clients’ self-identifying several risk factors.

The buzz about medical cannabis being a potential treatment for the cure of chronic diseases, especially those that are difficult to treat is poetic justice. The medicine is not designed by humans, but by nature. The prosaic truth behind medical cannabis is that the discussions about medical cannabis have reached a feverish pitch. This is especially seen where medical cannabis is culturally popular.

An increasing number of peer-reviewed studies indicate that opioid addiction has reduced when people use medical cannabis for chronic pain. Medical Cannabis has proved to be a viable treatment for specific untreatable conditions. The current barriers to medical cannabis are the lack of research and acceptance by institutions across the world.

Vichy International Limited believes two main paths have to be followed with respect to medical cannabis in the future. The human endocannabinoid system (ECS) continues to be an area of research. The thorough understanding of ECS would give better insights into developing medicines to target it. Secondly, the development was genetically modified plants that could give optimal ratios between THC & CBD.

At Vichy International Limited, they are able to produce enhanced genetically modified cannabis by understanding the body’s response to cannabinoids. The studies that began in 2008, have helped us interpret the interactions of THC with ECS and the physiological process involved.

Vichy International, with their well-researched medicines, will further reassess the risk factors of the insurance companies by removing medical cannabis as a risk of smoking. The company plans to develop medicines in the form of Sip by Sip Teas, capsules & pills, injections, and so on so that there is zero risk of ingestion of smoke into the lungs.

Vichy International plans to expand into manufacturing of medicines with their MCan coin offering. With unique benefits, such as Revenue Sharing, Dividend Sharing, and 1 free listed share, MCan Coin will be one of the most desirable assets to hold. The company has a current audited turnover of $60 million dollars and with expansion plans, they will grow to $600 million dollars in next 3 years. The Pre-ICO has begun and with unique benefits, investors will have immense growth in the next few years.